A study testing whether a new weekly shot, tirzepatide, can help people protect their kidneys.

Recruiting now. Registry record last updated May 6, 2025.

Who can join: Adults 18 to 65, have polycystic ovary syndrome (PCOS), BMI 27+.
What you take: tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 4.3 years; your own time in it is usually shorter.
What you get: Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 2Sponsor University of Colorado, DenverDrug tirzepatideClass GLP-1/GIPSites 1 USEnrollment target 126

What this study is for

Primary condition: Autosomal Dominant Polycystic Kidney. Also studied in: Obesity.

Full scientific study title: Glucagon-Like Peptide-1 Receptor Agonist in ADPKD.

Who can join

Age18 to 65SexAnyBMI27 or higher

Adults 18 to 65, have polycystic ovary syndrome (PCOS), BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

18-65 years of age
ADPKD diagnosis based on the modified Pei-Ravine criteria
Body-mass index of ≥27 kg/m\^2
Estimated glomerular filtration rate ≥ 30 mL/min/1.73m\^2
Mayo Classification of C, D, or E, calculated from a previous kidney ultrasound or MRI performed within the last 12 months

Key exclusion criteria

Diabetes mellitus
Tolvaptan usage or plans to initiate tolvaptan
History of hospitalization or major surgery within the last 3 months
Uncontrolled hypertension (systolic blood pressure \> 160 or diastolic blood pressure \>100 mm Hg)
Pregnancy, lactation, or unwillingness to use adequate birth control

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Colorado1 site

University of Colorado - Anschutz Medical Campus
Aurora, Colorado
Kristen Nowak, PhD, MPH303-724-4842Kristen.Nowak@cuanschutz.edu

Follow this trial

We email you if NCT06582875 changes status, adds new sites in your state, or if a similar trial opens for the same condition. No spam, opt out any time.

Timeline

Started enrolling: March 6, 2025. Expected completion: June 30, 2029. Last updated on ClinicalTrials.gov: May 6, 2025.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.